Conclusion of a non-exclusive rebate agreement under Section 130a(8) SGB V for the active substance clobazam (only dosage form TAB), ATC N05BA09, for the period 01/06/2026 to 31/05/2028 (plus option to extend once by 12 months)

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for the active substance clobazam (only dosage form TAB, ATC N05BA09) for the period 01/06/2026 to 31/05/2028, with an option to extend once by 12 months. It is an open accession model in which DAK-Gesundheit intends to conclude contracts with as many interested pharmaceutical companies as possible. The bidder must submit the required documents for contract conclusion or later accession by email.